Profiles for companies starting with 'e'
✉ Email this page to a colleague
Drugs and US Patents for e
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eirgen | TEMOZOLOMIDE | temozolomide | CAPSULE;ORAL | 203898-002 | Feb 10, 2016 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Eugia Pharma | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 214632-003 | May 25, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Edenbridge Pharms | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-002 | Jul 3, 2013 | RX | Yes | No | 9,259,421 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Eirgen | RAYALDEE | calcifediol | CAPSULE, EXTENDED RELEASE;ORAL | 208010-001 | Jun 17, 2016 | RX | Yes | Yes | 8,207,149 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Eli Lilly And Co | ZEPBOUND (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 217806-003 | Nov 8, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Eli Lilly And Co | RETEVMO | selpercatinib | TABLET;ORAL | 218160-001 | Apr 10, 2024 | RX | Yes | No | 10,137,124*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
